Table 1 Characteristics, initial stage and management modalities
From: Economics of the clinical management of lung cancer in France: an analysis using a Markov model
Histology | NSCLC | SCLC | |||||
|---|---|---|---|---|---|---|---|
Forms, number of patients | Local Op, 58 | Local Nop, 22 | LA-Ad, 21 | LA-Nad, 99 | Diffuse, 140 | Local, 36 | Diffuse, 52 |
Age | 70±11.2 | 59±11.4 | 55±9.2 | 63±11.3 | 55±9.2 | 63 (10.9) | 63±9.5 |
Death 18 months | 14 (24.1%) | 14 (64%) | 8 (38%) | 69 (70%) | 125 (89%) | 23 (64%) | 48 (92.3%) |
Management | |||||||
PC | 0 | 0 | 0 | 1 (1%) | 4 (2.9%) | 0 | 2 (3.8%) |
L1 | 58 (100%) | 22 (100%) | 22 (100%) | 98 (99%) | 136 (97.1%) | 22 (100%) | 50 (96.2%) |
Surgery only | 19 | — | — | — | — | — | — |
Surgery plus | 39 | — | 11 | — | — | — | — |
Radiation | — | 12 | — | 10 | — | — | — |
Chemotherapy | — | 5 | 9 | 65 | 124 | 9 | 40 |
Radiochemotherapy | — | 5 | 1 | 23 | 12 | 27 | 10 |
L2 | 17 (29.3%) | 5 (22.7%) | 18 (85.7%) | 61 (61.6%) | 58 (41.4%) | 13 (36.1%) | 18 (34.6%) |
Radiation | — | — | 6 | 16 | 3 | — | — |
Chemotherapy | 15 | 5 | 4 | 17 | 50 | 9 | 13 |
Radiochemotherapy | 2 | — | 6 | 30 | 5 | 4 | 5 |
